AUTHOR=Ni Huitong , Shi Jiaqi , Hu Ming , Zhou Naitong , Yang Shu 

TITLE=Cost-effectiveness analysis of Anaprazole versus Ilaprazole for the treatment of duodenal ulcers in China

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1407435

DOI=10.3389/fphar.2024.1407435

ISSN=1663-9812

ABSTRACT=<sec><title>Objective</title><p>Anaprazole, an innovative drug, has shown promise in initial clinical trials for patients with duodenal ulcers (DU) in China. This study aimed to evaluate the potential effects, safety, and cost-effectiveness of Anaprazole compared to Ilaprazole in the treatment of DU and the budgetary impact on the healthcare system.</p></sec><sec><title>Methods</title><p>Two multicentre, randomized controlled trials were used as data sources. The efficacy and safety of Anaprazole and Ilaprazole were compared using an anchored matching-adjusted indirect comparison (MAIC). A cost-utility analysis (CUA) was performed using a Markov model. A budget impact analysis (BIA) was conducted to evaluate the impact on the expenditure of the Chinese healthcare system. Deterministic and probabilistic sensitivity analyses were undertaken to test the uncertainty.</p></sec><sec><title>Results</title><p>The study findings indicated that Anaprazole and Ilaprazole have similar efficacy and safety in treating DU (OR = 1.05; 95% CI, 0.94–1.01; <italic>p</italic> = 0.35; OR = 0.63; 95% CI, 0.39–1.08; <italic>p</italic> = 0.12). The ICUR was 2,995.41¥/QALY, which is below the WTP threshold. The CUA results showed that Anaprazole is a cost-effective intervention with a probability of 85% at a given threshold. The results demonstrated strong robustness in the sensitivity analysis. Anaprazole imposed a low burden on the Chinese healthcare budget in the BIA.</p></sec><sec><title>Conclusion</title><p>Compared with Ilaprazole, Anaprazole has similar efficacy, safety, and high cost-effectiveness, while also impacting the total expenditure of the healthcare system.</p></sec><sec><title>Clinical Trial Registration:</title><p><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link>, identifier NCT04215653 and NCT02847455</p></sec>